Riskpilot← Back to searchSign inGet full accessBiomedical Scandinavia AB
ABActiveOrg 5591909477Fridensborgsvägen 148 1101Manufacture of other chemical products n.e.c. · NACE 2059Est. 20190 employees
Revenue 2025
SEK 12K
-86% vs 2024
EBITDA margin
-795.2%
+55% vs 2024
Equity ratio
10.5%
Financial strength
Net profit 2025
SEK -95K
+55% vs 2024
| Revenue | SEK 12K | -86% |
| EBITDA | SEK -95K | +55% |
| Net profit | SEK -95K | +55% |
| Total assets | SEK 489K | -15% |
| Equity | SEK 52K | +132% |
| Employees | 0 | — |
Legal name
Biomedical Scandinavia AB
Org number
5591909477
Legal form
Aktiebolag
NACE code
2059 · Manufacture of other chemical products n.e.c.
Founded
14 januari 2019
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska bedriva: -Utveckling och import och export av in-vitro diagnostiska produkter och biomedicinska produkter -Utveckling och import och export av hälsokost produkter -Konsultverksamhet inom hälsovård och äldreomsorg -Utbildning inom hälsovård och äldreomsorg
Address
Fridensborgsvägen 148 1101
Email
contact@sstkscandinavia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 422 | 379 | 224 | 84 | 12 |
| Staff expenses | — | −138 | −25 | −10 | −0 |
| EBITDA | 8 | −10 | 0 | −210 | −95 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 8 | −10 | 0 | −210 | −95 |
| Net financials | 7 | — | −0 | 0 | 0 |
| Profit before tax | 2 | −10 | −0 | −210 | −95 |
| Tax | −1 | — | −0 | — | — |
| Net profit | 1 | −10 | −0 | −210 | −95 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 445 | 264 | 590 | 575 | 489 |
| Equity | 51 | 51 | 51 | −159 | 52 |
| Long-term debt | 112 | 206 | 519 | 724 | 438 |
| Short-term debt | 282 | 7 | 20 | 10 | 0 |
| Total debt | 394 | 213 | 539 | 734 | 438 |
EBITDA margin
-795.2%
This company
15.8%
Market median
-5133% vs market
20212025
Equity ratio
10.5%
This company
38.2%
Market median
-73% vs market
20212025
Return on equity
-184.8%
This company
18.4%
Market median
-1104% vs market
20212025
Net profit margin
-794.7%
This company
8.1%
Market median
-9911% vs market
20212025
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
20212025
Debt / equity
8.49×
This company
0.62×
Market median
-1269% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JZ Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
SZ | Deputy Board Member | 2021 |
| Chairman | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Biomedical Scandinavia AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ji Zhou | Chief Executive Officer | 0 companies |
| Shan Zou | Deputy Board Member | 0 companies |
| Daniella Yuxuan Zhou | Chairman | 0 companies |